Drug Profile

VH 4524184

Alternative Names: GSK4524184; VH-184; VH-4524184

Latest Information Update: 19 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ViiV Healthcare
Developer GSK; ViiV Healthcare
Class Antiretrovirals
Mechanism of Action HIV integrase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II HIV infections

Most Recent Events

11 Mar 2025 Efficacy and adverse events data from a phase I trial released by ViiV Healthcare
15 Aug 2024 ViiV Healthcare completes a phase I trial for HIV infections (In volunteers) in USA (unspecified route) (NCT06310616)
11 Jul 2024 Phase-I clinical trials in HIV infections (In volunteers) in USA (PO) (NCT06310551)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com